|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-3-22
|
|
pubmed:abstractText |
Efficacy and safety of toremifene (TOR) 60 mgs/dayly/o.r. was compared with tamoxifen (TAM) 40 mgs/dayly/o.r. in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
119-24
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11261827-Aged,
pubmed-meshheading:11261827-Antineoplastic Agents, Hormonal,
pubmed-meshheading:11261827-Breast Neoplasms,
pubmed-meshheading:11261827-Disease-Free Survival,
pubmed-meshheading:11261827-Double-Blind Method,
pubmed-meshheading:11261827-Estrogen Antagonists,
pubmed-meshheading:11261827-Female,
pubmed-meshheading:11261827-Humans,
pubmed-meshheading:11261827-Middle Aged,
pubmed-meshheading:11261827-Neoplasm Metastasis,
pubmed-meshheading:11261827-Neoplasms, Hormone-Dependent,
pubmed-meshheading:11261827-Postmenopause,
pubmed-meshheading:11261827-Prospective Studies,
pubmed-meshheading:11261827-Survival Analysis,
pubmed-meshheading:11261827-Tamoxifen,
pubmed-meshheading:11261827-Toremifene
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
|
|
pubmed:affiliation |
The Medical Oncology Service, Nuestra Senyora Del Piltar Hospital, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
